These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23038609)

  • 1. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.
    Frampton JE
    Drugs Aging; 2012 Oct; 29(10):839-46. PubMed ID: 23038609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
    Freund KB; Hoang QV; Saroj N; Thompson D
    Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
    Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
    Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.
    García-Layana A; Figueroa MS; Araiz J; Ruiz-Moreno JM; Gómez-Ulla F; Arias-Barquet L; Reiter N
    Drugs Aging; 2015 Oct; 32(10):797-807. PubMed ID: 26442858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW; Bressler SB
    Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.
    Yang LP; McKeage K
    Drugs Aging; 2014 May; 31(5):395-404. PubMed ID: 24740170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
    Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
    Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
    Stewart MW
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept in wet AMD: specific role and optimal use.
    Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
    Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.